[1]袁 丹,徐思雨,甄伟兰,等.丁苯酞联合尼麦角林治疗血管性痴呆疗效及对患者血清神经视锥蛋白样蛋白1、脑源性神经营养因子水平的影响[J].陕西医学杂志,2023,52(9):1233-1236.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.028]
　YUAN Dan,XU Siyu,ZHEN Weilan,et al.Efficacy of butylphthalide combined with nicergoline in treatment of vascular dementia and their influence on serum VILIP-1 and BDNF levels[J].,2023,52(9):1233-1236.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.028]
点击复制

丁苯酞联合尼麦角林治疗血管性痴呆疗效及对患者血清神经视锥蛋白样蛋白1、脑源性神经营养因子水平的影响
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
52
期数:
2023年9期
页码:
1233-1236
栏目:
药物与临床
出版日期:
2023-09-05

文章信息/Info

Title:
Efficacy of butylphthalide combined with nicergoline in treatment of vascular dementia and their influence on serum VILIP-1 and BDNF levels
作者:
袁 丹1; 徐思雨2; 甄伟兰1; 王 莹1; 许 莉1
(1.北京航天总医院神经内科,北京100076; 2.中国中医科学院广安门医院心内科,北京 100053)
Author(s):
YUAN Dan; XU Siyu; ZHEN Weilan; WANG Ying; XU Li
(Department of Neurology,Beijing Aerospace General Hospital,Beijing 100076,China)
关键词:
血管性痴呆;  丁苯酞;  尼麦角林;  血管性认知障碍;  神经视锥蛋白样蛋白1;  脑源性神经营养因子
Keywords:
Vascular dementia;  Butylphthalide;  Nicergoline;  Vascular cognitive impairment;  Visinin-like protein 1;  Brain-derived neurotrophic factor
分类号:
R 749.13
DOI:
DOI:10.3969/j.issn.1000-7377.2023.09.028
文献标志码:
A
摘要:
目的:探讨丁苯酞联合尼麦角林治疗血管性痴呆(VaD)疗效及对患者血清神经视锥蛋白样蛋白1(VILIP-1)、脑源性神经营养因子(BDNF)水平的影响。方法:选取VaD患者72例,随机分为对照组(尼麦角林治疗)和观察组(丁苯酞+尼麦角林治疗)各36例。比较两组临床疗效,以及两组治疗前后蒙特利尔认知评估量表(MoCA)、简易精神状态量表(MMSE)和日常生活能力量表(ADL)评分; 比较两组治疗前后血清VILIP-1、BDNF水平及血液流变学指标(全血黏度高切和低切、血浆黏度及纤维蛋白原)的变化,以及两组不良反应发生情况。结果:对照组治疗总有效率低于观察组(P<0.05)。治疗后,两组MMSE、MoCA评分升高,ADL评分降低(均P<0.05); 与对照组比较,观察组MMSE、MoCA评分升高,ADL评分降低(均P<0.05)。治疗后,两组VILIP-1水平降低,BDNF水平升高(均P<0.05); 与对照组比较,观察组VILIP-1水平降低,BDNF水平升高(均P<0.05)。治疗后,两组全血黏度高切和低切、血浆黏度及纤维蛋白原水平降低(均P<0.05); 与对照组比较,观察组全血黏度高切和低切、血浆黏度及纤维蛋白原水平降低(均P<0.05)。两组不良反应总发生率比较差异无统计学意义(P>0.05)。结论:丁苯酞联合尼麦角林治疗VaD疗效满意,能够患者改善认知功能,提高BDNF水平,下调VILIP-1水平,且安全性较高。
Abstract:
Objective:To investigate the efficacy of butylphthalide combined with nicergoline in the treatment of vascular dementia(VaD)and their influence on serum visinin-like protein 1(VILIP-1)and brain-derived neurotrophic factor(BDNF)levels.Methods:Seventy-two patients with VaD were selected and randomly divided into control group(treated with nicergoline)and observation group(treated with nicergoline and butylphthalide),36 cases in each group.The clinical efficacy was compared between the two groups.The scores of MoCA,MMSE and ADL before and after treatment were compared between the two groups.The serum VILIP-1 and BDNF levels and hemorheological indexes(whole blood viscosity high cut and low cut,plasma viscosity and fibrinogen)before and after treatment were compared between the two groups.The incidence of adverse reactions was compared between the two groups.Results:The total effective rate in control group was higher than that in observation group(P<0.05).After treatment,MMSE and MoCA scores of two groups increased,and ADL score decreased(all P<0.05); compared with control group,MMSE and MoCA scores were increased,and ADL score was decreased in observation group(all P<0.05).After treatment,VILIP-1 level decreased and BDNF level increased in two groups(all P<0.05); compared with control group,the level of VILIP-1 was decreased and the level of BDNF was increased in observation group(both P<0.05).After treatment,the high cut and low cut whole blood viscosity,plasma viscosity and fibrinogen levels were decreased in two groups(all P<0.05); compared with control group,the high cut and low cut whole blood viscosity,plasma viscosity and fibrinogen levels were decreased in observation group(all P<0.05).There was no significant difference in total incidence of adverse reactions between two groups(P>0.05).Conclusion:Butylphthalide combined with nicergoline is effective in the treatment of VaD,which can improve cognitive function,increase BDNF level and down-regulate VILIP-1 level with high safety.

参考文献/References:

[1] 王亚妮,李维婷,袁成代,等.丁苯酞联合胞磷胆碱钠片治疗非痴呆性血管性认知障碍临床疗效及与同型半胱氨酸、甲状腺激素水平相关性研究[J].陕西医学杂志,2022,51(10):1285-1289.
[2] Mahinrad S,Sorond F,Gorelick PB.Therole of vascular risk factors in cognitive impairment and dementia and prospects for prevention[J].Clin Geriatr Med,2023,39(1):123-134.
[3] Kara B,Gordon MN,Gifani M,et al.Vascular and nonvascular mechanisms of cognitive impairment and dementia[J].Clin Geriatr Med,2023,39(1):109-122.
[4] 郑 勇,程 贝,陈亦辉,等.星蒌承气汤联合丁苯酞治疗缺血性脑卒中疗效及对患者氧化应激、血液流变学的影响[J].陕西中医,2023,44(2):191-194.
[5] 宁家辉,王 蕾.注射用益气复脉(冻干)联合尼麦角林片治疗轻度血管性认知障碍的临床研究[J].中西医结合心脑血管病杂志,2022,20(18):3408-3410.
[6] 余青龙,任 娟,周奇卿.血清SAA、BDNF、ALP水平与脑卒中后并发血管性认知功能障碍的关系[J].实用预防医学,2018,25(5):565-568.
[7] Babic-Leko M,Borovecki F,Dejanovic N,et al.Predictivevalue of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer's disease early detection and differential diagnosis in patients with mild cognitive impairment[J].J Alzheimers Dis,2016,50(3):765-778.
[8] 贾建平,陈生弟.神经病学[M].北京:人民卫生出版社,2013:217-222.
[9] 艾艳萍,丁 涛.多奈哌齐联合依达拉奉对脑梗死后血管性痴呆的疗效研究[J].西南国防医药,2018,28(6):528-530.
[10] 单永琳,刘国华.血管性痴呆的研究现状[J].医学综述,2017,23(8):1589-1594.
[11] Gallaway PJ,Miyake H,Buchowski MS,et al.Physicalactivity:Aviable way to reduce the risks of mild cognitive impairment,Alzheimer's disease,and vascular dementia in older adults[J].Brain Sci,2017,7(2):22.
[12] Arnaoutoglou NA,Arnaoutoglou M,Nemtsas P,et al.Color perception differentiates Alzheimer's disease(AD)from vascular dementia(VaD)patients[J].Int Psychogeriatr,2017,29(8):1355-1361.
[13] 刘 茹,张素芬,刘军贤,等.丁苯酞联合银杏叶提取物治疗帕金森认知功能障碍的临床疗效及对危险因素的影响[J].世界中西医结合杂志,2019,14(10):1442-1447.
[14] 吕 姣.尼麦角林对非痴呆型血管性认知功能障碍患者执行与认知功能的影响研究[J].检验医学与临床,2017,14(3):320-322.
[15] 陈康亮,施 慧,陈世震,等.尼麦角林联合加兰他敏治疗轻中度血管性痴呆患者的疗效与安全性[J].心血管康复医学杂志,2020,29(2):178-182.
[16] 王树峰,霍飞飞,刘国华,等.芪参还五胶囊联合丁苯酞对痰瘀互结型早期血管性痴呆患者认知功能障碍及p38丝裂原活化蛋白激酶通路变化的影响[J].世界中西医结合杂志,2023,18(1):104-108,113.
[17] Fransquet PD,Ritchie K,Januar V,et al.Is peripheral BDNF promoter methylation a preclinical biomarker of dementia?[J].J Alzheimers Dis,2020,73(2):645-655.
[18] Lourenco MV,Ribeiro FC,Sudo FK,et al.Cerebrospinal fluid irisin correlates with amyloid-β,BDNF,and cognition in Alzheimer's disease[J].Alzheimers Dement(Amst),2020,12(1):e12034.
[19] Fernández-García S,Sancho-Balsells A,Longueville S,et al.Astrocytic BDNF and TrkB regulate severity and neuronal activity in mouse models of temporal lobe epilepsy[J].Cell Death Dis,2020,11(6):411.
[20] 冀新红.丁苯酞治疗非痴呆性血管性认知功能障碍30例临床观察[J].陕西医学杂志,2018,47(1):117-119.
[21] 汪东良,王锦华,韩威威,等.血清学标志物Aβ1-42、sICAM-1、VILIP-1对脑梗死后血管性痴呆的预测价值[J].中华全科医学,2019,17(2):225-229.
[22] 李长琴.血管性认知障碍患者血清中NSE、GFAP、BDNF水平变化的研究[J].标记免疫分析与临床,2018,25(4):517-520.

相似文献/References:

[1]邓春颖,李海滨,毛文静,等.丁苯酞对阿尔茨海默病模型大鼠海马CA1 区脑源性神经营养因子和碱性成纤维生长因子蛋白表达影响的实验研究*[J].陕西医学杂志,2020,49(4):405.
　DENG Chunying,LI Haibin,MAO Wenjing,et al.Effect of dl-3-n-butylphthalide on the expression of BDNF and bFGF in CA1 region of hippocampus of Alzheimer disease rats[J].,2020,49(9):405.
[2]赵立伟,李 芳.替罗非班联合丁苯酞治疗进展性脑卒中对患者P-selectin、CD63、CD62p水平及预后的影响[J].陕西医学杂志,2021,50(1):89.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.024]
　ZHAO Liwei,LI Fang.Effect of tirofiban combined with butylphthalide on the levels of P-selectin,CD63,CD62p and prognosis in patients with progressive stroke[J].,2021,50(9):89.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.024]
[3]刘 斌,杨浩辉,任 伯,等.丁苯酞联合美多芭对帕金森病伴抑郁模型小鼠黑质纹状体Ⅱ型髓系细胞触发受体及小胶质细胞炎症标志物表达的影响[J].陕西医学杂志,2022,51(12):1477.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.003]
　LIU Bin,YANG Haohui,REN Bo,et al.Effects of butylphthalide combined with medoba on expression of TREM2 and microglia inflammatory markers in substantia nigra striatum of Parkinson's disease with depression model mice[J].,2022,51(9):1477.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.003]
[4]李 超,熊 兰,卢元明.银杏叶提取物联合茴拉西坦治疗血管性痴呆疗效观察[J].陕西医学杂志,2023,52(6):737.[doi:DOI:10.3969/j.issn.1000-7377.2023.06.022]
　LI Chao,XIONG Lan,LU Yuanming.Efficacy of ginkgo biloba extract combined with aniracetam in treatment of vascular dementia[J].,2023,52(9):737.[doi:DOI:10.3969/j.issn.1000-7377.2023.06.022]

备注/Memo

备注/Memo:
基金项目:北京市自然科学基金资助项目(7183299); 北京航天总医院创新基金资助项目(2018-511)
更新日期/Last Update: 2023-09-04